Skip to content

Impact of Side to Side Gastrojejunostomy on the Rate of Delayed Gastric Emptying After Pancreaticoduodenectomy (IPAD)

Impact of Side to Side Gastrojejunostomy on the Rate of Delayed Gastric Emptying After Pancreaticoduodenectomy: A Prospective Randomized Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04742166
Acronym
IPAD
Enrollment
166
Registered
2021-02-05
Start date
2021-07-07
Completion date
2024-10-01
Last updated
2023-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgical Technique

Brief summary

Prospective bi-centric randomized open-label study comparing side to side and end to side gastrojejunostomy in pancreaticoduodenectomy

Detailed description

Delayed gastric emptying is one of the main complications occurring after pancreatodudodenectomy, the incidence of which is estimated between 10 and 40% in the literature. Its occurrence leads to an alteration in post-operative quality of life (maintenance or resting of the nasogastric tube) and is the primary reason an increase in the length of hospital stay and therefore the cost of treatment. In addition, it predisposes to the risk of inhalation pneumopathy, which increases the risk of post-operative death. Various technical surgical points have been suggested by retrospective studies to reduce its incidence (pyloric preservation, respect for the left gastric vein, ante-colic positioning of the Child's handle, making a Y-shaped handle) but without ever being validated in randomized prospective studies. Recently three retrospective studies have highlighted the interest of performing a side to side l rather than an end to side gastro-jejunal anastomosis to reduce the rate of post-operative delayed gastric emptying.

Interventions

Lateral gastrojejunal Terminolateral gastrojejunal

Sponsors

Rennes University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patient over 18 years old * to benefit from a cephalic duodenopancreatectomy whatever the indication (benign and malignant tumor) * affiliated with a health insurance system * having received oral and written information about the protocol and having signed a free and informed written consent.

Exclusion criteria

* associated organ resection except for portal vein or hepatic artery resection. * history of gastric or esophageal resection * person subject to legal protection (safeguard justice, trusteeship and guardianship) and persons deprived of liberty * pregnant or breastfeeding women * patient participating in another clinical trial that may interfere with the protocol.

Design outcomes

Primary

MeasureTime frameDescription
Post-operative delayed gastric emptyingDay 90Occurrence of post-operative delayed gastric emptying (classified to the International Study Group for Pancreatic Surgery (ISGPS))

Secondary

MeasureTime frameDescription
Pancreatic fistulaUp to day 90Occurence of pancreatic fistula (classified according to the ISGPS classification)
Biliary fistulaUp to day 90Occurrence of biliary fistula
HaemorrhageUp to day 90Occurrence of haemorrhage according to the ISGPS classification
Food intake (liquid and solid)Up to five days after surgeryTime to oral food intake
First gasUp to five days after surgeryTime to the emission of the first gas
Occurrence of Clavien-Dindo complicationsUp to day 90
Albumin and prealbumin levelsUp to day 90
General Quality of Life Score for Digestive PathologiesUp to day 90
Gastrointestinal Quality of Life Index (GIQLI)Up to day 90
Mortality rateDay 30
Time to functional recovery (days) after surgeryDay 90Functional recovery defined as all of the following: * independently mobile at the preoperative level * sufficient pain control with oral medication alone * ability to maintain at least 50% daily required caloric intake * no intravenous fluid administration * no clinical signs of infection when other criteria were met
Pre-operative to 3-month post-operative weight ratioUp to day 90

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026